Healthcare Professionals

Providers Using Seraph 100 in the United States

For guidance on the use of Seraph 100 on COVID-19 patients, please follow the links below:

EUA Instructions for Use
EUA Health Care Providers Fact Sheet
EUA Patient Fact Sheet

For additional information/inquiries on the Seraph 100
Contact Us

MM-00020 Rev D

ExThera Medical Corporation
757 Arnold Drive, Suite B
Martinez, California 94553

Privacy Policy | Terms of Use | Contact Us
p: (925) 839-2060 | f: (925) 839-2075
[email protected]

The Seraph 100 has been authorized by FDA under an Emergency Use Authorization (EUA) to treat patients with COVID-19 infection. The Seraph 100 is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the Seraph 100 device under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

The ONCObind™ Procedure Hemoperfusion Filter is currently being studied under Investigational Device Exemption (IDE) and is not commercially available.

EXTHERA MEDICAL, the ExThera Medical Logo, SERAPH, the Seraph Logo, MICROBIND, and ONCOBIND are trademarks or registered trademarks of ExThera Medical Corporation in the U.S. and/or other countries.
2025 Exthera Medical. All rights reserved. MM-00028 Rev F

Website Disclaimer: External Content

ExThera Medical includes links to various publications and medical journals to help users find additional helpful information. These links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or approval by ExThera Medical of any of the products, services, or opinions of the linked websites. ExThera Medical bears no responsibility for the external site’s accuracy, legality, content, or subsequent links. Contact the external site for answers to questions regarding its content.

When you click on the various publications and medical journals, you will leave ExThera Medical’s website.

In case of questions, please get in touch with us here.

MM00024 Rev F

Go to Publications!